CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 24 enrolled
Drug / intervention
Venlafaxine Hydrochloride +1 moredrug
Likely dose
Venlafaxine Hydrochloride 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01260896
NCT01260896Phase 1Completed
CompareCT.gov

Randomized, 2-way Crossover, Bioequivalence Study of Venlafaxine Hydrochloride 150 mg Extended-Release Capsules and Effexor® XR 150 mg Extended-Release Capsules Administered as 1 x 150 mg Extended-Release Capsule in Healthy Subjects Under Fasting Conditions.

Teva Pharmaceuticals USA·interventional·Posted Dec 15, 2010·Updated Feb 21, 2011

In Brief

A Phase 1 clinical trial evaluating Venlafaxine Hydrochloride and Effexor® XR for Healthy. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The objective of this study was to compare the rate and extent of absorption of venlafaxine hydrochloride 150 mg extended-release capsules (test) versus Effexor® XR (reference) administered as 1 x 150 mg extended-release capsule under fasting conditions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesCanada
Collaborators--

Timeline

Phase 1CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 15, 2010
Enrollment StartSep 1, 2002
Primary CompletionOct 1, 2002
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 15.5 years ago

Interventions

Venlafaxine Hydrochloridedrug

150 mg Extended-Release Capsule

Effexor® XRdrug

150 mg Extended-Release Capsule